Quality control and the genotype concordance was 100 .Statistical AnalysisPatient clinicopathologic characteristics

Quality control and the genotype concordance was 100 .Statistical AnalysisPatient clinicopathologic MedChemExpress LED 209 characteristics were summarized as number and percentage of patients or median and interquartile range of values. The continuous factors were dichotomized at the median value within the cohort, with the exception of PSA nadir, which was dichotomized at 0.2 ng/mL because of its correlation with disease buy UKI 1 progression and PCSM [15,18]. The associations of polymorphisms and clinicopathologic variables with time to progression, PCSM, and ACM were assessed using the KaplanMeier analysis with log-rank test. Since the function and the optimal genetic model for these polymorphisms remain unknown, a series of genetic models (based on the minor allele’s dominant:Table 1. Clinicopathologic characteristics of the study population and analyses of factors that predicted disease progression, PCSM, and ACM during ADT.Variable No. of events* Median (months)No.* ( )Disease progressionPCSMACM Estimated mean (months)P{114 136 162No. of events*P{No. of events*Estimated mean (months)P{All patients73 (67?8) 306 (47.4) 339 (52.6) 228 24 65 132 105 215 21 0.368 49 136 0.154 57 131 109 ,0.001 192 (30.0) 204 (31.8) 245 (38.2) 187 17 79 105 134 25 23 148 120 25 0.005 12 147 ,0.001 25 34 103 131 140 89 ,0.001 207 (32.8) 195 (30.9) 230 (36.4) 164 17 69 104 133 25 22 134 137 26 0.004 22 154 ,0.001 37 36 87 140 115 92 ,0.001 35.0 (11.3?30) 311 (49.9) 312 (50.1) 223 19 85 201 24 0.113 28 144 115 ,0.001 49 110 131 100 ,0.001 0.19 (0.01?.37) 320 (50.3) 316 (49.7) 245 14 198 31 ,0.001 24 89 157 109 ,0.001 41 119 144 93 ,0.001 10 (5?7) 314 (49.4) 322 (50.6) 210 32 233 10 ,0.001 71 42 121 146 ,0.001 99 61 104 134 ,0.001 361 (56.2) 94 (14.6) 132 (20.6) 55 (8.6) 46 90 62 244 21 22 28 14 0.007 81 10 10 13 127 116 133 104 ,0.001 116 14 14 18 111 109 127 90 ,0.Age at diagnosis, yearsMedian (IQR),Clinical stage at diagnosisT1/TT3/T4/NMGleason score at diagnosis2?8?PSA at ADT initiation, ng/mLMedian (IQR),PSA nadir, ng/mLMedian (IQR),0.0.Time to PSA nadir, monthsMedian (IQR),Treatment modalityADT as primary treatmentADT for post RP/RT PSA failureNeoadjuvant/adjuvant ADT with RTBiomarkers Predict the Efficacy of ADTOthersAbbreviations: ADT, androgen-deprivation therapy; PCSM, prostate cancer-specific mortality; ACM, all-cause mortality; PSA, prostate-specific antigen; IQR, interquartile range; RP, radical prostatectomy; RT, radiotherapy. *Column subtotals do not sum to 645 for no. of patients, 444 for no. of disease progression, 114 for PCSM, and 162 for ACM due to missing data. { P values were calculated using the log-rank test. P#0.05 are in boldface. doi:10.1371/journal.pone.0054627.tBiomarkers Predict the Efficacy of ADTTable 2. Genotyping frequencies and the association of genotype with disease progression during ADT.P{Gene Polymorphism AR CAG repeatsGenotypeNo. of patientsNo. of eventsMedian (months)P*qHR (95 CI),21 21 22?3 .23 P-trend136 91 16581 65 11126 28 230.0.1.00 1.07 (0.76?.51) 0.92 (0.68?.24) 1.11 (0.84?.47) 1.02 (0.93?.12) 0.683 0.589 0.472 0.Abbreviations: ADT, androgen-deprivation therapy; HR, hazard ratio; 95 CI, 95 confidence interval; PSA, prostate-specific antigen. *P values were calculated using the log-rank test. HRs were adjusted for age, clinical stage, Gleason score, PSA at ADT initiation, PSA nadir, time to PSA nadir, and treatment modality. P#0.05 are in boldface. 26001275 doi:10.1371/journal.pone.0054627.t{with individuals carrying zero. Since metastatic disease.Quality control and the genotype concordance was 100 .Statistical AnalysisPatient clinicopathologic characteristics were summarized as number and percentage of patients or median and interquartile range of values. The continuous factors were dichotomized at the median value within the cohort, with the exception of PSA nadir, which was dichotomized at 0.2 ng/mL because of its correlation with disease progression and PCSM [15,18]. The associations of polymorphisms and clinicopathologic variables with time to progression, PCSM, and ACM were assessed using the KaplanMeier analysis with log-rank test. Since the function and the optimal genetic model for these polymorphisms remain unknown, a series of genetic models (based on the minor allele’s dominant:Table 1. Clinicopathologic characteristics of the study population and analyses of factors that predicted disease progression, PCSM, and ACM during ADT.Variable No. of events* Median (months)No.* ( )Disease progressionPCSMACM Estimated mean (months)P{114 136 162No. of events*P{No. of events*Estimated mean (months)P{All patients73 (67?8) 306 (47.4) 339 (52.6) 228 24 65 132 105 215 21 0.368 49 136 0.154 57 131 109 ,0.001 192 (30.0) 204 (31.8) 245 (38.2) 187 17 79 105 134 25 23 148 120 25 0.005 12 147 ,0.001 25 34 103 131 140 89 ,0.001 207 (32.8) 195 (30.9) 230 (36.4) 164 17 69 104 133 25 22 134 137 26 0.004 22 154 ,0.001 37 36 87 140 115 92 ,0.001 35.0 (11.3?30) 311 (49.9) 312 (50.1) 223 19 85 201 24 0.113 28 144 115 ,0.001 49 110 131 100 ,0.001 0.19 (0.01?.37) 320 (50.3) 316 (49.7) 245 14 198 31 ,0.001 24 89 157 109 ,0.001 41 119 144 93 ,0.001 10 (5?7) 314 (49.4) 322 (50.6) 210 32 233 10 ,0.001 71 42 121 146 ,0.001 99 61 104 134 ,0.001 361 (56.2) 94 (14.6) 132 (20.6) 55 (8.6) 46 90 62 244 21 22 28 14 0.007 81 10 10 13 127 116 133 104 ,0.001 116 14 14 18 111 109 127 90 ,0.Age at diagnosis, yearsMedian (IQR),Clinical stage at diagnosisT1/TT3/T4/NMGleason score at diagnosis2?8?PSA at ADT initiation, ng/mLMedian (IQR),PSA nadir, ng/mLMedian (IQR),0.0.Time to PSA nadir, monthsMedian (IQR),Treatment modalityADT as primary treatmentADT for post RP/RT PSA failureNeoadjuvant/adjuvant ADT with RTBiomarkers Predict the Efficacy of ADTOthersAbbreviations: ADT, androgen-deprivation therapy; PCSM, prostate cancer-specific mortality; ACM, all-cause mortality; PSA, prostate-specific antigen; IQR, interquartile range; RP, radical prostatectomy; RT, radiotherapy. *Column subtotals do not sum to 645 for no. of patients, 444 for no. of disease progression, 114 for PCSM, and 162 for ACM due to missing data. { P values were calculated using the log-rank test. P#0.05 are in boldface. doi:10.1371/journal.pone.0054627.tBiomarkers Predict the Efficacy of ADTTable 2. Genotyping frequencies and the association of genotype with disease progression during ADT.P{Gene Polymorphism AR CAG repeatsGenotypeNo. of patientsNo. of eventsMedian (months)P*qHR (95 CI),21 21 22?3 .23 P-trend136 91 16581 65 11126 28 230.0.1.00 1.07 (0.76?.51) 0.92 (0.68?.24) 1.11 (0.84?.47) 1.02 (0.93?.12) 0.683 0.589 0.472 0.Abbreviations: ADT, androgen-deprivation therapy; HR, hazard ratio; 95 CI, 95 confidence interval; PSA, prostate-specific antigen. *P values were calculated using the log-rank test. HRs were adjusted for age, clinical stage, Gleason score, PSA at ADT initiation, PSA nadir, time to PSA nadir, and treatment modality. P#0.05 are in boldface. 26001275 doi:10.1371/journal.pone.0054627.t{with individuals carrying zero. Since metastatic disease.